Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Edelstein

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Advances in Chronic Kidney Disease|June 21, 2008
Biomarkers of acute kidney injuryCharles L Edelstein
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2008
Mammalian target of rapamycin and caspase inhibitors in polycystic kidney diseaseCharles L Edelstein
Nephrology News & Issues|April 1, 2008
Therapeutic interventions for autosomal dominant polycystic kidney diseaseCharles L Edelstein
Cell Cycle (Georgetown, Tex.)|November 1, 2005
What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?Charles L Edelstein
Nature Reviews. Nephrology|October 6, 2015
Mechanisms and mediators of lung injury after acute kidney injurySarah Faubel, Charles L Edelstein
Seminars in Nephrology|February 4, 2014
Polycystic kidney disease: a case of suppressed autophagy?Kameswaran Ravichandran, Charles L Edelstein
Biomed Research International|August 29, 2014
Pathophysiology of cisplatin-induced acute kidney injuryAbdullah Ozkok, Charles L Edelstein
Nephron|July 27, 2022
The Pathophysiology of Left Ventricular Hypertrophy, beyond Hypertension, in Autosomal Dominant Polycystic Kidney DiseaseOzgur A Oto, Charles L Edelstein
Expert Opinion on Investigational Drugs|February 10, 2010
Novel targets for the treatment of autosomal dominant polycystic kidney diseaseFranck A Belibi, Charles L Edelstein
Kidney Research and Clinical Practice|February 20, 2016
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedsideHyun-Jung Kim, Charles L Edelstein
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Advances in Chronic Kidney Disease|June 21, 2008
Biomarkers of acute kidney injuryCharles L Edelstein
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2008
Mammalian target of rapamycin and caspase inhibitors in polycystic kidney diseaseCharles L Edelstein
Nephrology News & Issues|April 1, 2008
Therapeutic interventions for autosomal dominant polycystic kidney diseaseCharles L Edelstein
Cell Cycle (Georgetown, Tex.)|November 1, 2005
What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?Charles L Edelstein
Nature Reviews. Nephrology|October 6, 2015
Mechanisms and mediators of lung injury after acute kidney injurySarah Faubel, Charles L Edelstein
Seminars in Nephrology|February 4, 2014
Polycystic kidney disease: a case of suppressed autophagy?Kameswaran Ravichandran, Charles L Edelstein
Biomed Research International|August 29, 2014
Pathophysiology of cisplatin-induced acute kidney injuryAbdullah Ozkok, Charles L Edelstein
Nephron|July 27, 2022
The Pathophysiology of Left Ventricular Hypertrophy, beyond Hypertension, in Autosomal Dominant Polycystic Kidney DiseaseOzgur A Oto, Charles L Edelstein
Expert Opinion on Investigational Drugs|February 10, 2010
Novel targets for the treatment of autosomal dominant polycystic kidney diseaseFranck A Belibi, Charles L Edelstein
Kidney Research and Clinical Practice|February 20, 2016
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedsideHyun-Jung Kim, Charles L Edelstein
Pageof 12